Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology
Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology
Galmed在150名NASH和纖維化患者中進行的全球第3期Aramchol開放標籤部分的1年結果已發表在肝病學雜誌中
- The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)
- Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis
- Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology
- 該論文重新強調了Aramchol 300mg BID在代謝性功能障礙相關脂肪肝炎（MASH）患者中的顯著抗纖維化作用
- 數據已經通過3個客觀測量指標進行確認：NASH CRN、成對排序閱讀和人工智能（AI）定量數字分析
- 數字病理圖像分析（DIA）在抗纖維化試驗中生成了連續的組織學纖維化評分，比傳統病理學具有更高的靈敏度和更大的動態範圍，量化了抗纖維化效果
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology.
以色列特拉維夫，2024年9月25日 / PRNewswire / - 紐交所：GLMD）（「Galmed」或「公司」）， Galmed Pharmaceuticals Ltd是一家臨床階段的生物製藥公司，致力於肝臟、代謝和纖維炎症疾病宣佈，其全球III期Aramchol試驗（ARMOR）150名NASH患者和纖維化（ARCON）的開放標籤部分的1年結果已經在肝病學雜誌上發表
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間